Back

SARS-CoV-2 antigen rapid diagnostic test enhanced with silver amplification technology

Miyakawa, K.; Funabashi, R.; Yamaoka, Y.; Jeremiah, S. S.; Katada, J.; Wada, A.; Takei, T.; Shimizu, K.; Ozawa, H.; Kawakami, C.; Usuku, S.; Tanaka, N.; Yamazaki, E.; Shimizu, H.; Okabe, N.; Hasegawa, H.; Ryo, A.

2021-01-31 infectious diseases
10.1101/2021.01.27.21250659 medRxiv
Show abstract

Rapid diagnosis of COVID-19 is essential for instituting measures to prevent viral spread. SARS-CoV-2 antigen rapid diagnostic test (Ag-RDT) based on lateral flow immunochromatography assay (LFIA) principle can visually indicate the presence of SARS-CoV-2 antigens as a band. Ag-RDT is clinically promising as a point-of-care testing because it can give results in a short time without the need for special equipment. Although various antigen capture LFIAs are now available for rapid diagnosis for SARS-CoV-2 infection, they face the problems of low sensitivity. We have previously developed highly specific monoclonal antibodies (mAb) against SARS-CoV-2 nucleocapsid protein (NP) and in this study, we have employed these mAbs to develop a new LFIA that can detect SARS-CoV-2 NP in nasopharyngeal swab samples with higher sensitivity by combining them with silver amplification technology. We also compared the performance of our Ag-RDT against the commercially available Ag-RDTs using clinical samples to find that our newly developed LFIA performed best among tested, highlighting the superiority of silver amplification technology.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.